Last reviewed · How we verify

Anxiety due to Cardiac Asthma — Treatment Landscape & Competitive Intelligence

Anxiety due to Cardiac Asthma (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anxiety due to Cardiac Asthma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Opana Er OXYMORPHONE Endo Opioid Agonist Mu-type opioid receptor 1959-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Endo · 1 drug in Anxiety due to Cardiac Asthma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anxiety due to Cardiac Asthma:

Cite this brief

Drug Landscape (2026). Anxiety due to Cardiac Asthma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anxiety-due-to-cardiac-asthma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing